

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 416 804 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90309439.9

(51) Int. Cl.⁵: **A61K 31/18, A61K 9/08,
A61K 47/14, A61K 47/22**

(22) Date of filing: 29.08.90

(30) Priority: 04.09.89 JP 227575/89

(43) Date of publication of application:
13.03.91 Bulletin 91/11

(54) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: **YAMANOUCI PHARMACEUTICAL
CO. LTD.**
No. 3-11 Nihonbashi-Honcho, 2-chome
Chuo-ku
Tokyo(JP)

(72) Inventor: Konno, Yutaka
974-6 Sangamyo
Yaizu-shi, Shizuoka 425(JP)
Inventor: Katsuma, Masataka
Rm.201 No.1 Bldg. Surugadaindanchi, 1-3
Surugadal
Fujieda-shi, Shizuoka 426(JP)

(74) Representative: Geering, Keith Edwin et al
REDDIE & GROSE 16 Theobalds Road
London WC1X 8PL(GB)

(54) External preparation containing amusulosin.


- (57) An external preparation, for the treatment of dysuria or lower urinary tract disease, which comprises
- 1) at least one compound selected from amusulosin and salts thereof;
 - 2) aqueous alcohol, and
 - 3) at least one transdermal absorption promoting agent selected from aliphatic dicarboxylic acid diesters, nicotinic acid esters and isonicotinic acid esters, with or without addition of a terpene.

EP 0 416 804 A1

EXTERNAL PREPARATION CONTAINING AMUSULOSIN

The present invention relates to an external therapeutic preparation containing 5-[2-[[2-(o-ethoxyphenoxy)-ethyl]amino]propyl]-2-methoxybenzenesulfonamide or salt thereof as an active ingredient, useful for the improvement of dysuria and lower urinary tract disease.

5-[2-[[2-(o-Ethoxyphenoxy)-ethyl]amino]propyl]-2-methoxybenzenesulfonamide is a phenethylamine derivative of the following formula (I).



This compound, alias amusulosin, has potent and selective α_1 -receptor blocking activity (cf. EP-A-O 034 432). The α_1 -receptor blocking activity of amusulosin is higher than that of prazosin hydrochloride and, as a pharmacological action, reduces the contraction of the rabbit prostate, urethra and vesical triangle (trigone of the bladder) and of the human urethra and vesical triangle. Therefore, amusulosin can be clinically useful as an ameliorating agent for certain diseases such as dysuria and lower urinary tract disease. However, as these diseases occur more frequently in subjects of advanced age, the development of a sustained release preparation such as a long-acting oral preparation or a transdermal therapeutic system (hereinafter, referred to briefly as TTS) has been keenly demanded.

Elderly patients, particularly those bed-ridden, cannot be easily medicated by the oral route and, therefore, the advent of a TTS preparation, which may be administered more expediently than an oral preparation, is in demand. The demand for TTS is fortified by the fact that a TTS preparation is not subject to the first-pass effect, which is inevitable with an oral drug, that it insures sustained efficacy and that it can be withdrawn at any time.

However, since the permeability of the skin to most drugs is low, only limited kinds of drugs have heretofore been available in preparations of this type.

Furthermore, since the epidermal tissue acts as a barrier to prevent ingress of foreign matter, the absorption of a drug through the skin is not only greatly dependent on the intrinsic properties of the drug but also subject to the interaction between the drug and the remainder of the pharmaceutical composition and the recipient skin. Therefore, a TTS assuring increased transdermal absorption of one drug can hardly be predicted from the TTS technology established for another drug.

The same was true with amusulosin or a salt thereof, for which an external preparation useful for TTS was keenly demanded, and it was actually very difficult to design and manufacture an external preparation which would prove clinically useful.

As transdermal absorption promoting agent, a number of compounds have heretofore been proposed. These include 1-alkylazacycloheptan-2-ones, cis-olefins, aliphatic dicarboxylic acid diesters (e.g. diethyl sebacate etc.), nicotinic acid esters and so on (cf. U.S. Patents 3,989,816 and 4,390,520 and EP-A-271983).

It was known that amusulosin hydrochloride is only sparingly soluble in water and pure alcohol. We were therefore surprised that this compound showed no less than 10-fold greater solubility in aqueous alcohol.

As a result of extensive investigation on the transdermal absorption promoting activity of a large number of compounds to develop a TTS preparation of amusulosin hydrochloride, we have found that aliphatic dicarboxylic acid diesters, nicotinic acid esters and isonicotinic acid esters, used either independently or in combination or together with a terpene, are able to remarkably promote the transdermal absorption of amusulosin hydrochloride. It was surprising that the transdermal absorption promoting effect of a combination of amusulosin hydrochloride with such transdermal absorption promoting agent is by far greater in degree than that of the conventional combination of a drug with a transdermal absorption promoting agent.

It has been thus found that the use of aqueous alcohol increases the solubility of the active compounds of the present invention (amusulosin or a salt thereof) to a remarkable extent and, thus, facilitates the manufacture of pharmaceutical products. It was also found that the addition of a certain kind of ester results

in a marked improvement in the transdermal penetration of the active compound.

The present invention is, therefore, directed to an external preparations which contains aqueous alcohol and certain esters (hereinafter, referred to as a transdermal absorption promoting agent) as additives.

Amusulosin having the above formula (I) has excellent α -adrenaline receptor (α_1 receptor) blocking activity and can be utilized clinically as an ameliorating agent for dysuria and lower urinary tract diseases as mentioned above. It can also be of value as a therapeutic agent for hypertension, congestive cardioplegia, angina pectoris, prostatic hypertrophy, chromophilic cytoma, peripheral vascular disorder and so on.

The aforementioned salt of amusulosin include pharmaceutically acceptable salts, such as addition salts with inorganic acids (e.g. hydrochloric acid, sulfuric acid, hydrobromic acid, etc.) and with organic acids (e.g. acetic acid, oxalic acid, maleic acid, fumaric acid, citric acid, lactic acid, etc.). Particularly useful for clinical application is the hydrochloride, namely amusulosin hydrochloride (hereinafter referred as to AB-250, m.p. 254-256° C).

Amusulosin shown by formula (I) has one asymmetric carbon atom and there can exist isomers due to the presence of such a carbon atom. Such isomers all fall within the scope of the present invention either in each individual isolated form or in a mixture form. The (R)-form isomer is most preferable.

In the present invention, one or more amusulosin compounds is or are used in a total proportion of 0.5 - 10, preferably 1 - 5, wt.% based on the total pharmaceutical composition. Herein percentages are by weight unless otherwise indicated.

The alcohol to be used in the present invention is preferably a lower alcohol such as methanol, ethanol, propanol, isopropanol, butanol and so on, more preferably ethanol or isopropanol, most preferably ethanol. The alcohol content is preferably of the order of 40 to 60 percent, for the solubility of the compound is sharply increased in this range.

The preferred proportion of the aqueous alcohol is dependent on the amount of the above compound and the dosage form of the pharmaceutical composition but is e.g. from 2.5 to 98.5 percent by weight and more desirably from 5 to 97 percent by weight.

The ester to be used as the transdermal absorption promoting agent in the present invention is selected from among nicotinic acid esters, isonicotinic acid esters and aliphatic dicarboxylic acid diesters, mixtures of such esters, with or without addition of terpenes, more preferably aliphatic dicarboxylic acid diesters.

Examples of the aliphatic dicarboxylic acid diesters include the diesters of such aliphatic dicarboxylic acids as succinic acid, adipic acid, suberic acid, sebacic acid, maleic acid, etc. with lower alcohols of 1 to 6 carbon atoms such as methanol, ethanol, propanol, isopropanol, butanol, tert-butanol, pentanol, hexanol and so on.

The alcohol residues of nicotinic acid esters or isonicotinic acid esters include the above-mentioned alcohols and benzyl alcohol, to name but a few.

Since some of these absorption promoting agents, such as aliphatic dicarboxylic acid diesters, are considered to be concentration-dependent, the proportion of the absorption promoting agent must be determined in consideration of its kind. Usually, however, the transdermal absorption agent can be used in a proportion of 1 to 30 percent, and preferably 2 to 20 percent, based on the total composition.

Examples of terpenes which may be added as an optional component to the present external preparation include peppermint oil, orange oil, turpentine oil, l-menthol, d-limonene and so on.

The dosage form for the external preparation according to the present invention includes all preparations designed for application to the skin and capable of producing pharmacological effects locally or systemically, thus including such varied dosage forms as solutions in aqueous alcohols, spray dosage forms, gel ointments (creams) based on carboxy-vinyl polymers, general ointments, lotions, emulsions, cataplasms and the like.

The external preparation according to the present invention can be processed into a final product by selective use of a carrier or base optimal for the intended dosage form. The carrier or base may be selected from among those commonly employed which do not interfere with the solubility and transdermal penetration of the drug compound. The external preparation of the invention is best provided in the weakly alkaline to neutral pH range of from 5.5 to 8.5 and preferably 6 to 8.

The external preparation of the invention can be manufactured by dissolving the active compound in the aqueous alcohol and by adding the transdermal absorption promoting agent to the resultant solution with stirring to give homogeneous solution.

To ensure the homogeneity of the pharmaceutical composition, there may be incorporated, in suitable proportions, various emulsifiers such as polyoxyethylene-hydrogenated castor oil derivative (e.g. Nikkol HCO-60, trade name), polyoxyethylene-polyoxypropylene glycol ether (e.g. Pluronic F68, trade name), polyoxyethylene sorbitan monolaurate (Tween 20, trade name), polyoxyethylene monolaurate (Nikkol MYL-10, trade name) and so on.

In addition, ethylene glycol, propylene glycol, triethylene glycol or the like may be further incorporated for the purpose of preventing precipitation of crystals and accelerating the transdermal penetration of the active compound.

It is also possible to use white petrolatum, silicone oil (e.g. Silicone Fluid 360, trade name), gelatin, carboxyvinyl polymer, polyvinyl alcohol, (meth)acrylic acid-(meth)acrylate copolymer, etc., ointment bases such as liquid paraffin etc., humectants such as glycerin etc., and/or preservatives such as paraben etc. as formulating agents.

The dosage of the active component of the present preparation differs according to the kind of preparation, the age, weight, and symptom of a patient, etc., but is usually 0.01 to 6 mg/day, preferably 0.1 to 0.6 mg/day.

The present invention will now be illustrated in greater detail by way of Test Example and Examples, but it should be understood that the present invention is not limited thereto.

TEST EXAMPLE

1. Data on the solubility increasing effect of aqueous alcohol:

The solubility of AB-250 in water of pH 5-7 was 0.4% and that in ethanol was 0.03%.

In contrast, the solubility of the same compound in aqueous ethanol containing 60% of ethanol (Michaelis buffer containing 60% of ethanol, pH 7) was 4.8% and that in aqueous ethanol containing 50% of ethanol (Michaelis buffer containing 50% of ethanol, pH 8) was 5.1%. It is, thus, evident that the use of aqueous ethanol results in a remarkable increase in the solubility of the active compound.

More or less the same effect was obtained when isopropyl alcohol was used in lieu of ethanol.

2. Data on the improving effect on percutaneous absorption:

An in vitro isolated guinea pig skin penetration test was performed using AB-250.

(1) Preparation of samples:

Thus, AB-250 was dissolved, with warming (about 50°C), in the mixtures of ethanol with Michaelis buffer which are indicated in Table 1. Then, the transdermal absorption promoting agent or the like as indicated in Table 1 was added and mixed well as the third ingredient to prepare samples.

(2) Determination of transdermal penetration rate (flux):

From the abdominal region of the male Hartley guinea pig (6-7 weeks old), with hair clipped the previous day, the skin was isolated and mounted on a Franz diffusion cell.

Each AB-250 sample was added to the donor side and isotonic 10 mM potassium dihydrogen phosphate solution was added to the receptor side. The experiment was performed at a cell temperature of 37°C.

The receptor solution was sampled at 2-hour intervals up to 8 hours and the concentration of AB-250 in each sample solution was measured by high performance liquid chromatography (HPLC). The cumulative transdermal penetration amounts (mcg/sq.cm) of AB-250 at hours 2, 4, 6 and 8 were respectively determined and plotted on the ordinate while the time was plotted on the abscissa. From the resulting correlogram, the gradient was calculated and expressed as flux (penetration rate per unit area, mcg/sq.cm/hr).

This experiment was carried out in an open system and a closed system.

(3) Results:

EP 0 416 804 A1

The fluxes and flux ratios found in the above experiment are shown in Table 1.

Table 1

	Formulation	Proportions of Ingredients	Flux	Flux ratio
		(w/w%)	(mcg/sq.cm/hr)	
(i) Open system	*AB-250.EtOH.pH 8 Buffer	(5/47.5/47.5)	0.4	1
	*AB-250.EtOH.pH 7 Buffer	(5/47.5/47.5)	5.2	13
	AB-250/EtOH/pH 8 Buffer/DID	(5/45/45/5)	35.5	89
	AB-250/EtOH/pH 7 Buffer/DID	(5/45/45/5)	89.1	223
	AB-250/EtOH/pH 7 Buffer/DES	(5/45/45/5)	146.5	366
	AB-250/EtOH/pH 7 Buffer/DES	(1/47/47/5)	108.2	271
	AB-250/EtOH/pH 7 Buffer/DES	(1/49/49/1)	8.3	21
	AB-250/EtOH/pH 7 Buffer/DES	(1/48.25/48.25/2.5)	27.3	68
	AB-250/EtOH/pH 7 Buffer/DES/INB	(5/40/40/5/10)	814.9	2037
	AB-250/EtOH/pH 7 buffer/DES/PG	(2/44/44/5/5)	143.7	359
(ii) Closed system	AB-250/EtOH/pH 7 Buffer/DES	(5/45/45/5)	426.7	

note: "*" is control.

In Table 1, DID stands for diisopropyl adipate, DES for diethyl sebacate, INB for n-butyl isonicotinate, and PG for propylene glycol.

The above experiment indicated that the combined use of aqueous ethanol (ethanol-containing buffer) and the transdermal absorption promoting agent results in a remarkable increase in the flux value.

With regard to the effect of pH, higher transdermal penetration was achieved at pH 7 than at pH 8. With regard to the transdermal absorption promoting agent, INB and DES were more effective than DID. In the comparison between the open and the closed system, the closed system was conducive to relative higher transdermal penetration.

EXAMPLE 1 (Spray Dosage Form)

To a mixed solution of 2.0 g of AB-250, 46.5 g of ethanol and 46.5 g of Michaelis buffer (pH 7) was added 5.0 g of DES with stirring to give a homogeneous AB-250 solution. A pressure container (15 ml capacity, about 0.05 ml delivery per actuation) was filled with 10 ml of the above obtained solution to provide a spray dosage form.

EXAMPLE 2 (Spray Dosage Form)

To a mixed solution of 2.0 g of AB-250, 44.0 g of ethanol, 44.0 g of Michaelis buffer (pH 7) and 5.0 g of PG was added 5.0 g of DES with thorough stirring to give a homogeneous ABO-250 solution. Thereafter, the same procedure as described in Example 1 was followed to provide a spray dosage form.

EXAMPLE 3 (G I Ointment)

Using 30 g of purified water, 1.0 g of Carbopol 940 was swollen with stirring. Then, 0.5 g of

diisopropanolamin was added thereto for gelation. A mixed solution of 3.0 g of AB-250, 46 g of ethanol and 46 g of Michaelis buffer (pH 7) was prepared and 5 g of DES was added thereto and mixed well to give a homogeneous solution. Then, 68.5 g of this solution was gradually added to the Carbopol gel prepared above with constant stirring and the mixture was well kneaded to give a homogeneous gel ointment.

5

EXAMPLE 4

10 To a mixed solution of 1.0 g of AB-250, 48.6 g of ethanol and 32.4 g of Michaelis buffer (pH 7) was added 5.0 g of DES and the mixture was stirred well to give a homogeneous AB-250 solution. To this solution were added 10.0 g of triethylene glycol and 3.0 g of oil of peppermint and the mixture was stirred well to provide a homogeneous solution of AB-250.

15 While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the scope thereof.

Claims

20

1. An external preparation which comprises:

- 1) at least one compound selected from 5-[[2-[(o-ethoxyphenoxy)-ethyl]amino]propyl]-2-methoxybenzenesulfonamide and salts thereof as an active ingredient,
- 2) aqueous alcohol, and

25

- 3) at least one transdermal absorption promoting agent selected from aliphatic dicarboxylic acid diesters, nicotinic acid esters and isonicotinic acid esters, with or without addition of a terpene.

2. A preparation according to claim 1 wherein said aqueous alcohol is an aqueous ethanol.

3. A preparation according to claim 1 or 2 wherein said aqueous alcohol contains 40 to 60% by weight of alcohol.

30

4. A preparation according to any preceding claim wherein said transdermal absorption promoting agent comprises aliphatic dicarboxylic acid diester.

5. A preparation according to claim 4 wherein said aliphatic dicarboxylic acid diester comprises diethyl sebacate.

35

6. A preparation according to claim 5 wherein said transdermal absorption promoting agent comprises a mixture of diethyl sebacate and n-butyl isonicotinate.

40

45

50

55



European
Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 90 30 9439

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
D,A	EP-A-0 034 432 (YAMANOUCHI) * Claims 1,3,7-8; page 14, lines 1-14 *	1	A 61 K 31/18 A 61 K 9/08 A 61 K 47/14 A 61 K 47/22
A	EP-A-0 194 838 (YAMANOUCHI) * Claims 1,3,5; column 2, lines 40-41,46-48,61-64 *	1,2	
A	EP-A-0 027 286 (PROCTER & GAMBLE) * Claims 1,2; page 13, line 26 *	1,2,5	
A	EP-A-0 182 635 (NITTO) * Claims 1,3,6,8; page 11, lines 8-11 *	1,2,6	
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
			A 61 K
The present search report has been drawn up for all claims			
Place of search The Hague		Date of completion of search 21 November 90	Examiner SCARPONI U.
<div>CATEGORY OF CITED DOCUMENTS</div> <div><div>X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention</div><div>E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons s: member of the same patent family, corresponding document</div></div>			